5065.0 Drug Policy & Pharmacy Services

Wednesday, November 11, 2009: 8:30 AM
This session will consider the impact on safety and costs and/or the lack of muscle in regulation around patent rights, direct-to-consumer-advertising, and off-label advertising, and several initiatives that are being introduced to improve patient safety and outcomes while simultaneously reducing costs.
Session Objectives: 1. Identify safety, cost-containment and regulatory issues around direct-to-consumer advertising, and off-label advertising. 2. Assess the impact of the Drug Price Competition and Patent Term Restoration Act on generic entry of products and generic competition. 3. Describe the cost-containment and improved patient outcome potential of medication therapy management and the use of patient medication lists.
Maggie Huff-Rousselle, MA, MBA, PhD

8:30 AM
Patient education through pharmaceutical marketing: A pilot study of PhRMA's Office of Accountability consumer comment process
Ano L. Lobb, MPH, Samuel Wertheimer, MPH, Shannon Sweeney, MPH, Salma Batool-Anwar, MD, Dennis Goulet, BA and Marian Bihrle, BS
8:45 AM
Return on Investment Calculators: Development, Considerations, and Limitations
Michelle Dembiski, MPH Candidate, Krysten A. Chin, BA, Candice D. Presseau, MA, Stan Kachnowski, MA, Rudi Odeh-Ramadan, Pharm D, Stephen Buck, MBA, Mohammed H. Mahbouba, MD, MS and Donald Klepser, PhD, MBA
9:00 AM
Safety Promoting Behaviors: An Innovative and Feasible Method to Determine the Effectiveness of a Pharmacy Benefit Management Program
M. Paige Powell, PhD, Jeroan J. Allison, MD, MS, Joshua S. Richman, MD, PhD, Kenneth G. Saag, MD, Hugh Tilson, MD, DrPH, Patrick Irvine, MD, Joel Kavet, MPH, ScD and Norman W. Weissman, PhD
9:30 AM

See individual abstracts for presenting author's disclosure statement and author's information.

Organized by: Medical Care

CE Credits: Medical (CME), Health Education (CHES), Nursing (CNE), Public Health (CPH)

See more of: Medical Care